Introduction {#s1}
============

Obesity and type 2 diabetes mellitus are risk factors for cancer development at several tissues \[[@R01]-[@R05]\] and cardiovascular diseases \[[@R06]-[@R9]\]. Currently, the prevalence of type 2 diabetes has increased significantly in developed countries \[[@R10]\]. Animal models of spontaneous obese and type 2 diabetes have been reported and contributed to studies on human diabetic syndromes \[[@R11]-[@R13]\] and an association between obesity/diabetes and carcinogenesis \[[@R14]-[@R16]\]. They include NSY mice and KK-Ay mice that are mild obese, hyperglycemic and hyperinsulinemia \[[@R17]-[@R19]\]. Massive obesity mice, C57BL/6J-Lee (ob/ob) mice lack leptin and show mild hyperglycemia and hyperinsulinemia. These mice revert to normal glycemia at 7 months of age \[[@R17], [@R20], [@R21]\]. C57BL6/KsJ + Leprdb (*db*/*db*) mice with mutations impairing leptin receptor signaling have severe hyperglycemia, hyperinsulinemia and obesity as early as 10 days of age \[[@R22]-[@R24]\]. At 4 - 5 months of age, the animal became more severely hyperglycemic with hypoinsulinemia, weight loss and early death \[[@R17], [@R20], [@R25]\]. In addition, a relatively new polygenetic model of spontaneous obese type 2 diabetes mellitus mice named as Tsumura Suzuki obese diabetes (TSOD) mice, has been established as an inbred line in 1992 and the clinical symptoms of diabetes have been characterized by Suzuki et al \[[@R26]\]. Male TSOD mice constantly showed signs of obesity and urinary sugar with increased intake of food and heavy body and fat weights. Blood glucose and insulin levels are constantly high during their life \[[@R26], [@R27]\]. Carcinogenesis using KK-Ay mice \[[@R28]-[@R30]\], ob/ob mice \[[@R31], [@R32]\], and db/db mice \[[@R33], [@R34]\] was well studied to determine an association between obesity/diabetes and oncogenesis. However, carcinogenesis in the TSOD mice has not yet been reported.

In this study, we first evaluated oncogenesis in the male TSOD mice in comparison with the Tsumura Suzuki non-obesity (TSNO, non-diabetic control) mice. A chemical carcinogen, 4-nitroquinoline 1-oxide (4-NQO), was used to produce tumors in the tongue and esophagus. Furthermore, we examined the expression of several proinflammatory cytokines and inflammatory enzymes in the target tissues.

Materials and Methods {#s2}
=====================

Animals, diet and carcinogen {#s2a}
----------------------------

Twenty-eight male TSOD and 28 TSNO mice at 8 weeks of age used in this study were purchased from the Institute for Animal Reproduction (Ibaraki, Japan). Four mice were housed in a plastic cage in a non-barrier-sustained animal room maintained at 23 ± 2 °C with 50±10% humidity and a 12/12 h light/dark cycle. They were maintained on a basal diet MF (Oriental Yeast Co., Ltd, Tokyo) and tap water *ad libitum*. All animal experiments were approved and carried out following the Guideline for Animal Experimentation of Gifu University. 4-NQO (98% pure, CAS no. 56-57-5, Wako Pure Chemical Ind., Osaka, Japan) was used as a carcinogen to induce tongue and/or esophageal tumors in this study.

Treatments {#s2b}
----------

TSOD and TSNO mice were divided into two groups, respectively. One group (n = 20) was treated with 4-NQO (98% pure, CAS no. 56-57-5, Wako Pure Chemical Ind., Osaka, Japan) in drinking water for 8 weeks at a concentration of 20 ppm, and then the mice were given tap water without 4-NQO for 20 weeks. The other group (n = 8) was given tap water without 4-NQO throughout the experimental period. At week 28, all mice were sacrificed and complete necropsy was done on all mice.

Measurement of biochemical parameters {#s2c}
-------------------------------------

At sacrifice, the blood samples were collected and centrifuged to obtain plasma samples to be determined. Concentrations of the following determinants were assayed using a Model 680 microplate reader (BIO-RAD Laboratories, CA, USA) with a kit for each substance: levels of plasma glucose (Glucose CII-Test; Wako Pure Chemical Industries, Osaka, Japan), total cholesterol (T-Cho) (Cholesterol E-Test; Wako Pure Chemical Industries), triglyceride (Triglyceride E-Test; Wako Pure Chemical Industries), high-density lipoprotein (HDL)-cholesterol (HDL-cholesterol E-Test; Wako Pure Chemical Industries) and low-density lipoprotein (LDL)-cholesterol (Cholestest LDL; Daiichi Pure Chemicals, Tokyo, Japan).

Histopathology {#s2d}
--------------

The animals were sacrificed at 28 weeks to evaluate the occurrence of preneoplasms and neoplasms in both the tongue and esophagus. At killing by exsanguination under a deep ether anesthesia, macroscopic examination was carefully performed and the numbers of grossly visible tumors in the tongue and esophagus were counted, and then these tissues with or without tumors were processed for histopathological examination after being fixed in 10% buffered formalin. For a histological examination, the tissues fixed in 10% buffered formalin were embedded in paraffin block, and then the histological sections were stained with hematoxylin and eosin.

Epithelial lesions (dysplasia and neoplasia) in both tissues were diagnosed according to our previous study \[[@R35]\]. To determine the multiplicity of the tongue and esophageal lesions, the tissue specimens were examined for gross lesions without the use of any magnification aid.

A short-term experiment to measure esophageal cytokines and chemokines {#s2e}
----------------------------------------------------------------------

Sixteen male TSOD (8 weeks old) and 16 male TSNO mice (8 weeks old) were obtained from the Institute for Animal Reproduction. They were given tap water with or without 20 ppm 4-NQO for 8 weeks. At 8 weeks after the start of the experiment, the esophagus with or without lesions was processed to assay the content of cytokines (Mouse TNF-α Quantikine ELISA Kit, Cat \# PMTA008; Mouse Quantikine IL-1β ELISA Kit, Cat \# SMLB00C; Mouse IFN-γ Quantikine ELISA Kit, Cat \# SMIF00; Mouse IL-6 Quantikine ELISA Kit, Cat \# PM6000B; and Mouse IL-17 Quantikine ELISA Kit, Cat \# PM1700) and chemokines (Mouse CXCL1/KC Quantikine ELISA Kit, Cat \# PMKC0B; Mouse CCL3/MIP-1α Quantikine ELISA Kit, Cat \# PMMA00; and Mouse CXCL2/MIP-2 Quantikine ELISA Kit, Cat \# MM200) using the R&D Systems ELISA kits (R&D Systems, Inc., Minneapolis, MN, USA), which was obtained from Funakoshi Co., Ltd (Tokyo, Japan).

To quantify esophageal tissue cytokines and chemokines, 50 mg of esophageal tissue was extracted using 500 µL of 5 M guanidine HCl and 50 mM Tris-HCl (pH 8.0) with a protease inhibitor. The extracts were centrifuged at 15,000 g for 30 min at 4 °C to remove insoluble materials. Levels of TNF-α, IL-1β, IFN-γ, IL-6, IL-17, KC, MIP-1α and MIP-2 in the supernatant fractions were determined by sandwich ELISA using the kits from R&D Systems, Inc. ELISA was performed according to the manufacturer's instructions. To quantify, the 1:20 dilutions of the supernatants of esophageal tissue homogenates were added into 96-well microplates. These microplates were coated with polyclonal goat anti-mouse cytokine or chemokine antibodies, which were used as capturing antibodies and biotinylated polyclonal rabbit anti-mouse cytokine antibodies for detection. Streptavidin-HRP and tetramethylbenzidine sulfonate were added as color indicators. Plates were read at 490 nm immediately after the color reaction was stopped with acid. Standard curves were prepared like the samples using diluted standard solutions. All standards and samples were run triplicate.

Statistical analysis {#s2f}
--------------------

The Fisher's exact probability test was used for statistical analysis of the incidence of lesions. The other results expressed as the mean ± SD were analyzed by Student-Newman-Keuls multiple comparison test using the GraphPad InStat software (version 3.05, GraphPad Software, San Diego, CA). A level of P \< 0.05 was considered to be statistically significant.

Results {#s3}
=======

Body, liver and visceral fat weights {#s3a}
------------------------------------

Mean body weight of the TSOD mice with or without 4-NQO treatment at the end of study was significantly heavier than that of the TSNO mice with or without 4-NQO exposure, as shown in [Table 1](#T1){ref-type="table"}. Similarly, mean weight of visceral (epididymal, mesenteric, retroperitoneal and perinephric) fat in the TSOD mice with or without 4-NQO treatment was significantly heavier than that of TSNO mice with or without 4-NQO exposure.

###### Body, Liver and Visceral Fat Weights

  Treatment                    TSOD mice                                    TSNO mice                   
  ---------------------------- -------------------------------------------- ------------- ------------- -------------
  Body weight (g)                                                                                       
    Initial                    35.1 ± 1.2[a](#nt101){ref-type="table-fn"}   35.4 ± 2.0    23.6 ± 2.2    25.1 ± 1.7
    Final                      63.3 ± 2.2                                   64.5 ± 2.7    43.5 ± 2.1    45.4 ± 2.1
  Liver weight (g)             1.64 ± 0.12                                  1.59 ± 0.20   1.48 ± 0.17   1.52 ± 0.14
  Visceral fat weight^b^ (g)   5.52 ± 0.21                                  5.62 ± 0.19   1.39 ± 0.17   1.59 ± 0.21

Mean ± SD. ^b^Visceral fat includes epididymal, mesenteric, retroperitoneal and perinephric fats.

Biochemistry in the serum {#s3b}
-------------------------

As listed in [Table 2](#T2){ref-type="table"}, the values of serum glucose, triglyceride, total cholesterol, HDL and LDL in the TSOD mice were higher than those of TSNO mice regardless of the treatment of 4-NQO.

###### Clinical Chemistry

                              TSOD mice     TSNO mice                  
  --------------------------- ------------- ------------- ------------ ------------
  Glucose (mg/dL)             171 ± 29^a^   135 ± 19      90 ± 21      102 ± 13
  Triglyceride (mg/dL)        233 ± 39      113 ± 61      33.6 ± 4.6   16.4 ± 3.5
  Total cholesterol (mg/dL)   227 ± 22      183 ± 46      137 ± 13     121 ± 12
  HDL-cholesterol (mg/dL)     116 ± 20      107 ± 13      160 ± 16     139 ± 20
  LDL-cholesterol (mg/dL)     37.8 ± 9.1    24.0 ± 11.2   12.2 ± 1.3   18.8 ± 4.7

^a^Mean ± SD.

Incidence and multiplicity of proliferative lesions in the tongue and esophagus {#s3c}
-------------------------------------------------------------------------------

4-NQO treatment induced proliferative lesions in the tongue and esophagus of TSOD and TSNO mice. Proliferative lesions developed in the tongue ([Fig. 1](#F1){ref-type="fig"}) and esophagus ([Fig. 2](#F2){ref-type="fig"}) included squamous cell dysplasia, papilloma and carcinomas. The incidences and multiplicities are summarized in [Tables 3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}. The incidence and multiplicities of tongue proliferative lesions were comparable in the TSOD and TSNO mice ([Table 3](#T3){ref-type="table"}). On the other hand, the incidences of squamous cell papilloma (60%) and carcinoma (50%) in the esophagus of TSOD mice were significantly larger than those (30% and 0%) of TSNO mice when both types of mice were given 4-NQO ([Table 4](#T4){ref-type="table"}). In addition, the multiplicity (1.50 ± 1.70) of esophageal squamous cell papilloma in the TSOD mice given 4-NQO was significantly higher than that (0.60 ± 1.14) of TSNO mice that received 4-NQO ([Table 4](#T4){ref-type="table"}).

![Histopathology of tongue proliferative lesions developed in male TSOD mice treated with 20 ppm 4-NQO in drinking water: (a) moderate dysplasia; (b) squamous cell papilloma; (c) carcinoma *in situ*; (d) invasive squamous cell carcinoma. Hematoxylin and eosin stain, bar = 100 µm.](wjon-08-097-g001){#F1}

![Histopathology of esophageal proliferative lesions in male TSOD mice treated with 20 ppm 4-NQO in drinking water: (a) moderate dysplasia; (b) squamous cell papilloma; (c) carcinoma *in situ*; (d) invasive squamous cell carcinoma. Hematoxylin and eosin stain, bar = 100 µm.](wjon-08-097-g002){#F2}

###### Tongue Proliferative Lesions

  Lesions                   TSOD mice treated with 4-NQO   TSNO mice treated with 4-NQO         
  ------------------------- ------------------------------ ------------------------------ ----- -------------
  Dysplasia                 100                            4.80 ± 1.44^a^                 100   3.95 ± 1.47
  Papilloma                 15                             0.20 ± 0.52                    10    0.10 ± 0.31
  Squamous cell carcinoma   20                             0.30 ± 0.66                    25    0.30 ± 0.57
  Total tumors              30                             0.50 ± 0.89                    30    0.40 ± 0.68

^a^Mean ± SD.

###### Esophageal Proliferative Lesions

  Lesions                   TSOD mice treated with 4-NQO   TSNO mice treated with 4-NQO         
  ------------------------- ------------------------------ ------------------------------ ----- -------------
  Dysplasia                 100                            6.55 ± 1.73^a^                 100   6.75 ± 3.32
  Papilloma                 60^b^                          1.5 0 ± 1.70^b^                30    0.60 ± 1.14
  Squamous cell carcinoma   50^c^                          0.75 ± 0.91                    0     0
  Total tumors              70                             2.25 ± 2.29^d^                 30    0.60 ± 1.14

^a^Mean ± SD. ^b-d^Significantly different from the values of the TSNO mice treated with 4-NQO (^b^P \< 0.05, ^c^P \< 0.001, and ^d^P \< 0.01).

TNF-α, IL-1β, IFN-γ, IL-6, IL-17, KC, MIP-1α and MIP-2 protein expression by ELISA {#s3d}
----------------------------------------------------------------------------------

ELISA assays were conducted to determine the levels of TNF-α, IL-1β, IFN-γ, IL-6, IL-17, KC, MIP-1α and MIP-2 protein expression in the esophagus ([Fig. 3](#F3){ref-type="fig"}). In the TSOD mice, the expression of all the proteins ([Fig. 3a-g](#F3){ref-type="fig"}) except MIP-2 ([Fig. 3h](#F3){ref-type="fig"}) was significantly increased when 4-NQO was administered (P \< 0.001, P \< 0.01 or P \< 0.05). In the TSNO mice, the expression of all the proteins ([Fig. 3a-e, g](#F3){ref-type="fig"}), except KC ([Fig. 3f](#F3){ref-type="fig"}) and MIP-2 ([Fig. 3h](#F3){ref-type="fig"}), was significantly elevated when 4-NQO was administered (P \< 0.001, P \< 0.01 or P \< 0.05). When compared with the TSNO mice given 4-NQO, the expression of TNF-α protein ([Fig. 3a](#F3){ref-type="fig"}) was significantly up-regulated in the TSOD mice that received 4-NQO (P \< 0.01).

![Measures of esophageal cytokines and chemokines in a short-term experiment using 16 male TSOD and 16 male TSNO mice given tap water with or without 20 ppm 4-NQO for 8 weeks. At 8 weeks after the start of the experiment: (a) TNF-α, (b) IL-1β, (c) IFN-γ, (d) IL-6, (e) IL-17, (f) CXCL1/KC, (g) CCL3/MIP-1α, and (h) CXCL2/MIP-2.](wjon-08-097-g003){#F3}

Discussion {#s4}
==========

Obesity and type 2 diabetes mellitus are risk factors of cancer development, including oral and esophageal cancers \[[@R24], [@R36]-[@R44]\]. As to esophageal cancer, esophageal adenocarcinoma, but not squamous cell carcinoma, is closely related to obesity \[[@R36]\]. In the current study, we demonstrated that development of esophageal squamous cell carcinoma is associated with obesity and diabetes mellitus. However, in this study, we did not show an association between oral squamous cell carcinoma and obesity/diabetes mellitus. The reason for this is unknown, but we would speculate that carcinogenic stimuli of 4-NQO are too strong in the oral cavity. Dixon et al \[[@R45]\] have recently reported an association between diabetes mellitus development of adenocarcinoma in the esophagus and gastric cardia, and the association was independent of obesity \[[@R45]\].

Analysis of clinical chemistry in the current study showed the TSOD mice are obese, diabetic, hypertriglyceridemia and hyperlipidemia, when compared with the TSNO mice. Hyperlipidemia is reported to be a risk for developing oral cancer \[[@R38]\] and lymph node metastasis of esophageal cancer \[[@R46]\]. In our study, we did not observe distant metastases of tongue and esophageal cancers in TSOD and TSNO mice. However, the numbers of oral and esophageal tumors per animal in the TSOD mice that received 4-NQO were higher than those of TSNO mice given 4-NQO.

In the current study, we found that 4-NQO-induced carcinogenesis in the TSOD mice was susceptible in the esophagus when compared with the tongue. The exact mechanism(s) for the findings are not known, but our analysis indicated that several pro-inflammatory cytokines and chemokines in the esophagus of the TSOD mice that received 4-NQO were highly expressed when compared with the TSNO mice. Both tumor-inhibiting and tumor-enhancing inflammatory cells can be found in neoplastic lesions in several tissues, including oral cavity and esophagus \[[@R47]-[@R49]\]. Inflammation could increase the risk of cancer development by providing bioactive molecules, such as cytokines and chemokines, from cells that infiltrate the tumor microenvironment \[[@R50]\]. The role of several inflammatory mediators in events of carcinogenesis includes their capability to generate reactive oxygen and nitrogen species; their potential mutagenic effects; and involvement in mechanisms for epithelial-mesenchymal transition, angiogenesis, and metastasis.

We observed tongue and esophageal dysplasia as well as neoplasms in the TSOD and TSNO mice that received drinking water containing 4-NQO. Squamous cell dysplasia is a precursor lesion for oral \[[@R51]\] and esophageal squamous cell carcinoma \[[@R52]\]. Although there are a few animal models of oral-esophageal cancer \[[@R53]-[@R55]\], TNOD mice are suitable for understanding and analyzing an association between obesity/diabetes and esophageal carcinogenesis when used a carcinogen 4-NQO. Also, involvement of inflammatory stimuli in oncogenesis in these tissues can be investigated. Our future studies include basic research of chemoprevention of oral and esophageal squamous cell carcinogenesis.
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